Moderna Inc

Strong Q3 commercial + profit, plus disciplined spending - Revenue $1.3B in Q3 (+29% YoY), with management highlighting stronger-than-expected performance in both U.S. and international (mix roughly 60% U.S. / 40% international). - Net income $162M (improvement of $362M YoY), EPS $0.38 vs loss $0.51 prior year. - Company ended Q3 with ~$8.0B cash & investments and said it is reducing cash costs by ~10% YoY (financial discipline maintained while investing).

2026 outlook upgraded meaningfully (growth + cash) - Full-year revenue growth framework raised to +15% to +25% (from previously up to +10%). - Cost of sales framework unchanged at $1.7B but includes a $900M litigation charge. - R&D expense lowered by $200M to $2.7B (more wind-down/efficiency). - Cash-cost target lowered by another $200M to ~ $3.8B for 2026; CapEx lowered to $200M. - End-of-year cash & investments projected $8.1B–$8.3B (and without the $2.6B convertible/capped call net proceeds, cash projection would be $5.5B–$5.7B). - No dividends or buybacks mentioned.

Key pipeline/commercial milestones (opportunities) - mFLUSIVA (Moderna’s mRNA influenza vaccine) received FDA approval (adults 50–64, and accelerated for 65+)—described as Moderna’s 5th approved product and 1st mRNA influenza vaccine to reach market. - Canada approvals also secured for mFLUSIVA and mCOMBRIAX (brand name referenced in transcript). - COVID/respiratory updates: mNEXSPIKE updated strain approvals for the 2027 season in multiple markets; deliveries underway for updated COVID vaccines. - International partnership update: 5-year Mexico agreement for COVID-19 vaccine supply. - Oncology headline: Intismeran (autogene) + Keytruda in resected melanoma (INTerpath-001) showed 42% reduction in risk of recurrence/death (HR 0.58, p<0.001) vs pembrolizumab alone at first interim; 2-year RFS ~82.2% vs 70%. - Additional analysis highlighted 49% reduction (MITT) and Moderna framed it as the first positive Phase 3 individualized cancer vaccine result and as showing added benefit beyond anti-PD-1 in adjuvant melanoma.